CD274 and osteosarcoma: In parallel, the immune checkpoint inhibitors that have revolutionized clinical oncology during the last two decades, have not shown yet impressive results against recurrent osteosarcoma, while the predictive value of widely applied biomarkers, such as PD-L1 expression, must be clarified.